In this study, researchers aim to explore new treatments for Alzheimer's disease (AD) in people at risk due to a genetic mutation. AD causes memory problems and affects thinking. The study assesses if the treatments can slow or prevent brain changes linked to AD.

Key Points:

• The study involves two stages, each lasting 4 years. In Stage 1, participants may receive a study drug or a placebo (a substance with no active drug). In Stage 2, all participants will receive the study drug.
• Participants must be at least 18 years old and either have a family history of a specific genetic mutation linked to AD or be unaware of their genetic status.
• The study requires regular visits for tests, including brain scans and memory tests, to monitor the drug's effects.

Eligible participants should be healthy with no symptoms of AD and agree to certain conditions, like not donating blood during the study. Those with certain medical conditions or taking specific medications may not be eligible.